India is not left out on the vaccine scene. The world’s largest manufacturer, the Serum Institute of India, in Pune in the west of the country, has produced 60 million doses of the AstraZeneca vaccine every month since the fall, to which it has acquired the rights. India approved it in January under the name Covishield, as well as another, Covaxin, co-developed by Bharat Biotech, based in Hyderabad. But these two vaccines are at the center of a controversy raised by scientists and patient associations, who criticize opaque and hasty validation processes.
Read also the related article: